All News

Cancer passed in utero, trading art for health care, urinary incontinence in young women and more in the ob/gyn week in review.

This is a common uterine condition. What's your diagnosis?

Cranberry-containing products may be more than just a folk remedy for urinary tract infections (UTIs). A systematic review and meta-analysis published in the Archives of Internal Medicine concludes that cranberry-containing products offer women protection against UTIs, particularly those prone to recurrent infections.

In a systematic review of UAE versus other surgical interventions for symptomatic uterine fibroids, researchers concluded that UAE offers substantial improvements in symptoms of uterine fibroids but may not help women who want to retain their reproductive potential.

From nutritional supplements to pregnancy support products to spa services, more ObGyn practices--and physicians' offices in general--are turning to ancillary products as additional sources of revenue.

This is a middle aged woman with pelvic discomfort and normal menses. Sagittal images of the uterus are shown. What is your diagnosis?

Use of selective serotonin reuptake inhibitors (SSRIs) during pregnancy is associated with smaller fetal head circumference-a prenatal marker of brain volume-and with higher risk of preterm birth (< 37 weeks), according to findings from a prospective population-based study from the Netherlands.

Pregnant women who are unable or unwilling to quit smoking can help improve lung function in their newborns by taking vitamin C daily.

A new study found that placement of a midurethral sling can halve the rate of incontinence after prolapse surgery

Babies born to moms who were in hurricanes during pregnancy have higher rates of health problems at birth, according to a working paper issued by the National Bureau of Economic Research.

A small but vocal group of advocates actively lobby against circumcision, and ACOG and AAP find “insufficient evidence” to recommend it routinely. What’s your take?

This patient had a history of pelvic pain and five weeks amenorrhea with no h/o spotting. What is your diagnosis?

A study found substantially improved survival of offspring for women who received prenatal multiple micronutrient supplementation and early invitation to food supplementation.

A review of women's health studies reveals that the hormonal fluctuations women experience throughout their lives can change conditions in the mouth, allowing for health changes.

A new study indicates that some female cancer survivors develop breast cancer as a consequence of radiation exposure.

Social media is opening up what you can do with your practice.

Letters discuss the myriad of issues affecting the practice of specialties. Joshua A. Copel responds.

A reversible topical male contraceptive may be close r to reality, based of the results of a randomized trial.

Bleeding disorders can create problems with reproductions.

A review of several lawsuits covering acid solution errors, prolapse, fetal weight, breast cancer diagnosis, and complications following fibroid embolization.

In this chapter, Dr. Owen reviews the diagnosis or cervical insufficiency; patient selection for history-indicated (prophylactic), physical examination-indicated (Emergent), and ultrasound-indicated (urgent) cerclage; placement and removal of cerclagel and adjunctive therapies.

A new assessment of what late and variable decelerations mean.

A population-based study indicates that extremes in birthweight lead to an increased risk of stillbirth.

Hyperemesis causes a variety of problems to mothers during pregnancy and a tiered approach can prove beneficial.

Bleeding disorders can create problems with reproductions.

The United States Food and Drug Administration (FDA), under its priority review program, recently approved PerjetaTM (pertuzumab), a HER2/neu receptor antagonist indicated in combination with HerceptinR (trastuzumab), another HER2 therapy, and docetaxel for treatment of HER2-positive metastatic breast cancer (BCa) in women who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease.

Analysis by the United States Food and Drug Administration (FDA) of compounded 17α-hydroxyprogesterone caproate (17P) shows the samples meet the potency and total purity standards for Makena, the branded version of the drug. Testing was done on 16 samples of bulk 17P active pharmaceutical ingredients (API) in response to questions from K-V Pharmaceuticals, Makena’s sponsor, about potency and purity of the compounded product.

Although risks increase after an EP, a history of EP alone does not warrant closer-than-usual monitoring during a future pregnancy.